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Aim To purify the platelet aggregation inhibitor from Echis 
multisquamatis snake venom (PAIEM) and characterize its 
effect on platelet aggregation and HeLa cell proliferation.
Methods Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and matrix assisted laser desorp-
tion/ionization time-of-flight (MALDI-TOF) were used for 
PAIEM identification. Platelet aggregation in the presence 
of PAIEM was studied on aggregometer Solar-AP2110. The 
changes of shape and granularity of platelets in the pres-
ence of PAIEM were studied on flow cytometer COULTER 
EPICS XL, and degranulation of platelets was estimated 
using spectrofluorimetry. Indirect enzyme-linked immu-
nosorbent assay was used for the determination of target 
of PAIEM on platelet surface. An assay based on 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was 
used to evaluate the effect of PAIEM on the proliferation of 
HeLa cells in cell culture.
Results The molecular weight of the protein purified from 
Echis multisquamatis venom was 14.9 kDa. Half-maximal in-
hibitory concentration (IC50) of PAIEM needed to inhibit ad-
enosine diphosphate (ADP)-induced platelet aggregation 
was 7 μM. PAIEM did not affect thrombin- or ADP-induced 
platelet activation, but it did prevent binding of the anti-
IIb antibody to glycoprotein IIb/IIIa (GPIIbIIIa)-receptor of 
adhered platelets and inhibited the viability of HeLa cells 
by 54%.
Conclusion As a member of the disintegrin family, PAIEM 
inhibited platelet aggregation and cell proliferation possi-
bly by blocking integrin-mediated interactions. However, 
it did not impair cellular signaling causing any changes in 
platelet shape and granularity and did not affect ADP-in-
duced platelet degranulation. This disintegrin was shown 
to be a potent inhibitor of integrin-mediated cellular inter-
actions including platelet aggregation or cancer cell pro-
liferation.
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Platelet aggregation represents a multistep adhesion pro-
cess that is accompanied by fibrin polymerization and leads 
to thrombus formation (1). This multistep process is triggered 
by platelet interaction with the subendothelium extracellu-
lar matrix containing collagen and von Willebrand factor or 
by soluble inducers such as adenosine diphosphate (ADP), 
thrombin or tromboxane A2 (2). Platelet aggregation inhibi-
tors used as therapeutic drugs or laboratory reagents mainly 
target separate distinct stages of the process and can be di-
vided into several groups. Purinergic receptors’ antagonists 
and well-known anti-platelet drugs ticagrelor, clopidogrel, 
prasugrel, and other similar drugs are used in clinical trials (3) 
and act mainly on P2Y12 ADP-receptor (4). Another common 
anti-platelet agent, aspirin, inhibits thromboxane A2 synthe-
sis in platelets and thus reduces platelet response to ago-
nists (5). There are many novel cyclooxygenase-2 inhibitors 
that are as potent as acetylsalicylic acid but still have some 
comparative disadvantages (6). Phosphodiesterase inhibi-
tors decrease the hydrolysis of intracellular cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophos-
phate (cGMP) and thus attenuate platelet aggregation (7). 
Some of them are already registered as therapeutic agents, 
such as cilostazol or dipyridamole.
Peptides and proteins that contain the Arg-Gly-Asp (RGD) 
sequence are able to inhibit the interaction between plate-
let glycoprotein IIb/IIIa (GPIIb/IIIa) and fibrinogen, prevent-
ing platelet aggregation (8). There are many GPIIb/IIIa an-
tagonists in clinical use, such as abciximab, a Fab-fragment 
of a monoclonal antibody to GPIIb/IIIa (9), and tirofiban 
and eptifibatide, heterocyclic organic compounds (10,11).
Disintegrins that contain RGD or Lys-Gly-Asp (KGD) se-
quences have also been identified in snake venoms (8). 
Naturally occurring disintegrins could provide a template 
for the development of synthetic peptide antagonists. 
Within that context, purified and characterized snake ven-
om disintegrins could be used in clinical trials and studies 
of platelet aggregation.
The aim of this study was purification, partial characteriza-
tion, and analysis of anti-platelet effect of the disintegrin 
from the venom of Echis multisquamatis (PAIEM).
MATERIAL AND METHODS
Material
Platelet-rich plasma samples were obtained from the 
blood of healthy donors. Each experiment was replicated 
using platelets from the blood of three different donors. 
Volunteers signed informed consent prior to blood sam-
pling according to the Helsinki declaration. Platelet-rich 
plasma was prepared from human citrated blood by cen-
trifugation at 1000 rpm for 20 min. Washed platelets were 
obtained from platelet-rich plasma by centrifugation for 
15 min at 1500 rpm and re-suspended in 0.004 M HEPES 
buffer (N-(2-hydroxyethyl)-piperazine-N’-2-ethanesulfonic 
acid) of рН 7.4 (0.137 М NaCl, 0.003 М КСІ, 0.001 М MgСІ2, 
0.006 М glucose, 0.003 M NaH2PO4).
Mouse CD61 monoclonal antibody, goat anti-mouse-
horseradish peroxidase conjugated (HRP) antibody, Q-
sepharose, Superdex G-75, ABTS (2,2’-azino-di-[3-ethyl-
benzothiazoline-6 sulfonic acid] diammonium salt), MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, HEPES buffer, and Amicon Ultra-0.5 mL Centrifugal 
Filters (UFC500324, Merck Millipore) were purchased from 




The crude venom of Echis multisquamatis was dissolved 
in 0.05 M Tris-HCl buffer of pH 7.4 (tris-buffered saline, 
TBS) and gel-filtered through Superdex G-75 column. The 
column volume was 60 ml, with a flow rate of 1 ml/min. 
Fractions that exhibited anti-aggregatory activity were 
collected and prepared for the ion-exchange chromatog-
raphy.
Ion-exchange chromatography
Q-sepharose column was pre-equilibrated with 0.05 M 
Tris-HCl buffer of pH 8.9. The column volume was 3 ml, 
with a flow rate of 1 ml/min. The solution was eluted with a 
step gradient of NaCl, and the fraction that contained low-
molecular weight fraction was eluted at the ionic strength 
of 1 M. The active fraction was further concentrated and 
desalted using Amicon Ultra-0.5 mL Centrifugal Filters 
(UFC500324, Merck Millipore).
SDS-PAGE and mass-spectrometry
The molecular weights and purity of PAIEM were deter-
mined by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) 15% gel according to Laemmli (12). 
Matrix assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) analysis of purified PAIEM was performed 
using a Voyager-DE (Applied Biosystems, Foster City, 
CA, USA). Н+-matrix ionization of polypeptides with 
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sinapine acid (Sigma-Aldrich) was used. Results were ana-
lyzed by Data Explorer 4.0.0.0 (Applied Biosystems) (13).
Flow cytometry
The shape and granularity of resting platelets in platelet-
rich plasma after the incubation with PAIEM vs TBS were 
monitored by flow cytometer as described elsewhere (14). 
The suspension of washed human platelets in 0.004 M 
HEPES buffer of рН 7.4 was incubated with 0.1 mg/mL of 
PAIEM or the equal volume of TBS for the control in the 
presence of 0.01 M CaCl2. Platelet activation was induced 
by 0.125 National Institute of Health units per mL (NIH/
mL) of thrombin (15). Parameters of frontal and orthogonal 
light-dissipation were monitored for the detection of the 
change of shape and granularity of platelets during their 
activation at 1, 1.5, 2, 2.5 minutes from activation point.
Spectrofluorimetric measurements of platelet 
degranulation
Platelet activation was registered with pH-sensitive fluores-
cent dye acridine orange that is accumulated in secretory 
granules according to their ΔpH and is released after acti-
vation. Platelet-rich plasma with or without addition of 10 
μg/mL of PAIEM was preincubated at 37°C for 10 minutes, 
and fluorescence measurements started after the acridine 
orange application. Changes in fluorescence intensity 
were measured in a stirred thermostatted cuvette at ex-
citation and emission wavelengths of 490 and 530 nm, re-
spectively, with slit bands 5 nm each. The ADP (2 µM) was 
applied at the steady state level of acridine orange fluores-
cence. The traces were normalized (Ft/F0) to similar data in 
the absence of platelets. The exocytotic release was calcu-
lated as percentage of total accumulated dye at the steady 
state conditions.
Indirect ELISA
Indirect enzyme-linked immunosorbent assay (ELISA) was 
used for the analysis of PAIEM interactions with activated 
platelets. Washed human platelets in 0.004 M HEPES buf-
fer of рН 7.4 were added to the wells of 96-well tissue 
culture plate (Nunc) and then activated by 30 µM of ADP. 
Wells were gently washed with HEPES buffer trice. An-
tibody CD61 (specific to IIb subunit of IIb/IIIa platelet re-
ceptor) was added to the first row of wells, to the second 
row antibody CD61 was added alongside with PAIEM (0.05 
mg/mL). Probes were incubated for 1 hour at +37°C, then 
wells were gently washed thrice with HEPES buffer and 
secondary antibody goat anti-mouse-HRP was added 
to all wells. After 1-hour incubation, the activity of 
HRP was monitored using ABTS (2,2’-azino-di-[3-ethyl-ben-
zothiazoline-6 sulfonic acid] diammonium salt). The optical 
density of the end product was measured at 416 nm. The 
competition between PAIEM and CD61 antibody was re-
corded as the difference in signal received in the presence 
or absence of PAIEM.
Cell culture
The HeLa cells (cervical cancer cells) and mouse aortic en-
dothelial cells (MAEC) were grown in Iscove’s modified Dul-
becco’s medium (Sigma) supplemented with 10% fetal bo-
vine serum (FBS) and gentamicin (50 μg/mL). All cells were 
incubated at 37°C in 5% CO2. The medium was replaced 
the next day, and cells were incubated under the same 
conditions in Iscove’s medium containing 10% FBS, gen-
tamicin (50 μg/mL), and 6 µg/mL PAIEM for 48 hours.
Cell viability assay
Cell viability was measured by MTT assay. Cells were plat-
ed at 15000 cells per well in 96-well plates and incubat-
ed with 100 μL complete medium containing 1 mg/mL 
MTT at 37°C for 4 hours followed by solubilization with di-
methyl sulfoxide (Sigma). The absorbance at 540 nm was 
measured with a microplate reader. The proliferation was 
expressed as percentage of the viable cell number of the 
control (non-treated cells) and PAIEM-treated cells. Cell 
proliferation rate was calculated as [(1−ODexperimental group)/
ODcontrol group] × 100% (16).
Statistical analysis
Statistical analysis was performed using Microsoft Excel. 
All assays were performed in series of three replicates and 
the data were fitted with standard errors using “Statistica 7”. 
The results were presented as means ± standard error (SD). 
The difference between the groups was analyzed by one-
way ANOVA. The level of statistical significance was set at 
P < 0.05.
RESULTS
Purification of the platelet aggregation inhibitor from 
Echis multisquamatis venom
After the crude venom was separated into several fractions 
by ion-exchange chromatography on Q-Sepharose and 
the fraction containing PAIEM was purified on Superdex 
G-75, PAIEM displayed as a single peptide chain on SDS-
PAGE profile (Figure 1), since the mobility was the same in 
the presence and absence of 2% beta-mercaptoethanol. 
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MALDI-TOF-MS analysis showed a molecular mass of 14,9 
kDa (Figure 2).
PAIEM effect on platelets
The inhibitory action of PAIEM
PAIEM displayed the inhibitory action on platelet aggre-
gation in platelet-rich plasma in dose-dependent manner 
(Figure 3). The PAIEM IC50 on ADP-induced platelet aggre-
gation was 10 µg/mL (approximately 7 μM), and maximum 
inhibition (about 80%) was shown at 50 µg/mL (Figure 3). 
However, total inhibition could not be attained by raising 
PAIEM concentration (up to 300 µg/mL).
The longer the incubation time of platelet-rich plasma with 
PAIEM, the greater was the inhibitory effect of the PAIEM 
on ADP-induced platelet aggregation (Figure 4). Its inhibi-
tory effect on platelet aggregation reached 90% when the 
incubation time was prolonged to 12 minutes.
Platelet activation in the presence of PAIEM
After showing the inhibitory action of PAIEM on platelet 
aggregation, it was mandatory to know whether PAIEM 
inhibits activation of platelets. To achieve this goal, we 
studied thrombin-induced activation of washed plate-
lets in the presence of PAIEM. Dimethyl sulfoxide (DMSO) 
of 1% was chosen as the positive control. It presumably 
prevents platelet activation as an inhibitor of cyclooxy-
genase-1 (17).
FIGURE 1. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) of platelet aggregation inhibitor 
from the venom of Echis multisquamatis (PAIEM) eluted from 
Q-Sepharose and then purified on Superdex G-75 column. M – 
molecular weight markers.
FIGURE 2. Matrix Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) analysis of purified platelet aggregation inhibitor 
from the Echis multisquamatis (PAIEM) snake venom. According to MALDI-TOF spectrometry, the protein has molecular weight 14.9 
kDa. Other two peaks marked on the graph correspond to 1/2 charged molecules.
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Platelets without blood components were incubated with 
50 μg/mL of PAIEM or equivalent volume of DMSO and 
then activated by 0.125 NIH/mL thrombin. The activation 
was recorded by flow cytometry, which allows estimating 
the size of the cells (the change of front light scattering) 
and the granularity of their cytoplasm (the degree of lat-
eral light scattering) (18). Since the activation of platelets is 
accompanied by changes in their shape and granulation, 
the change of front and lateral light scattering showed the 
level of platelet activation (Figure 5).
Two minutes after the stimulation, thrombin reduced the 
quantity of platelets in zone of resting cells to 18 ± 5% in 
control probe (Figure 5, panel A2) and to 16 ± 8% in probe 
with PAIEM (Figure 5, panel A2). Meanwhile, DMSO distinct-
ly inhibited platelet activation – the level of resting platelets 
in probe with 1% DMSO was 32 ± 6% (Figure 5, panel C2).
Thus, we assumed that PAIEM does not affect platelet re-
sponse to thrombin stimulation. We also tested platelet 
degranulation in the presence of PAIEM by applying the 
spectrofluorimetric registration of release of granular con-
stituents using pH-sensitive fluorescent dye acridine or-
ange (19).
The effect of PAIEM per se on the acidification of platelet 
secretory granules was estimated at the steady state con-
ditions of pH-sensitive dye accumulation. The application 
of PAIEM (50 μg/mL) or TBS in equal volume did not affect 
the proton gradient of platelet secretory granules. Then 
platelets were stimulated by ADP (2.5 μM) to detect the 
release of secretory granules constituents. The degranula-
tion was estimated as percentage of dye release from the 
total accumulated acridine orange. The comparative anal-
ysis showed that ADP-stimulated platelet degranulation 
was not affected by PAIEM (Figure 6). Thus, we assumed 
that PAIEM inhibits platelet aggregation and does not af-
fect platelet degranulation or agonist-induced reactivity.
Effect of PAIEM on anti-IIb binding to activated platelets
The principal platelet receptor, providing formation and 
stabilization of fibrin-platelet thrombus, is GPІІb/ІІІа. The 
activation of platelets triggers a conformational change 
in the receptor GPIIb/IIIa that leads to the formation of a 
high-affinity ligand-binding state (20). Multiple binding of 
fibrinogen molecule to GPIIb/IIIa receptors is a crucial pro-
cess in platelet aggregation.
Therefore the possible interaction of PAIEM and GPIIb/IIIa 
was analyzed. For this purpose activated platelets were ad-
sorbed on the surface. The binding of anti-GPIIb to GPIIb/
IIIa receptors of adhered platelets was estimated in the 
presence or absence of PAIEM by ELISA using labeled goat 
anti-mouse antibody. We showed that PAIEM significantly 
FIGURE 3. Dose-dependence curve of the level of adenosine 
diphosphate-induced (2.5 µM) aggregation of human platelets 
in platelet rich plasma in the presence of platelet aggregation 
inhibitor from the Echis multisquamatis (PAIEM) snake venom. 
Boxes and whiskers represent the mean values ± standard 
error, respectively (data of 3 typical experiments made in 
triplicate). *P < 0.05 as compared to the control.
FIGURE 4. The effect of preincubation of platelet-rich plasma 
with 5 μg/mL of platelet aggregation inhibitor from the Echis 
multisquamatis (PAIEM) snake venom for 2, 4, 6, 8 12 minutes 
on the aggregation of platelets induced by 2.5 μM of adenos-
ine diphospate. Data represent the mean values ± standard er-
ror (data of 3 typical experiments made in triplicate), *P < 0.05 
as compared to the control.
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inhibited the binding of anti-GPІІb antibodies to activated 
platelets (Figure 7A, B) and assumed that PAIEM prevented 
platelet aggregation via interaction with GPIIbIIIa and so 
was probably an GPIIb/IIIa antagonist.
Effect of PAIEM on proliferation of HeLa and MAIEC cells 
in cell culture
After showing that PAIEM was a classical disintegrin that in-
hibited platelet aggregation by binding to GPIIb/IIIa integ-
rins of platelets, we tested the action of PAIEM on prolifera-
tion activity on HeLa and MAIEC cells. PAIEM was used at 6 
µg/mL that is near IC50 for ADP-induced platelet aggrega-
tion. Proliferation index was analyzed as the main param-
eter of cell division and functionality.
Cell viability after treatment with 6 µg/mL of PAIEM was 
evaluated by the MTT assay. After 48 hours of incubation, 
addition of PAIEM decreased the proliferative index by 54% 
compared to the control group (Figure 8).
DISCUSSION
In the present study, we isolated and purified a novel disin-
tegrin from Echis multisquamatis snake venom by two-step 
chromatography to homogeneity confirmed by SDS-PAGE 
and determined that the molecular weight of the PAIEM 
was 14.9 kDa. We also characterized the PAIEM inhibitory 
activity on human platelets, finding that PAIEM dose-de-
pendently inhibited ADP-induced platelet aggregation 
with IC50 of 10 µg/mL (approximately 7 μM). Typically, the 
IC50 values of disintegrins vary from 30 to 300 nM. However, 
in our study, PAIEM exerted its action without the neces-
sary preincubation with platelet-rich plasma, although its 
inhibitory effect could be slightly increased by incubation 
up to 12 minutes.
Disintegrins are antagonists of integrin receptors that in-
hibit their interaction with individual ligands, and in this 
way play important role in many biological processes in-
cluding platelet aggregation, inflammation, atherosclero-
FIGURE 5. Flow cytometry of washed human platelets activated by 0.125 NIH/mL of thrombin. 1-3 – 1, 2, and 3 minutes after 
the stimulation, respectively. A. – control probe; B. – in the presence of 50 μg/mL of platelet aggregation inhibitor from the Echis 
multisquamatis (PAIEM) snake venom; C. – in the presence of 1% dimethyl sulfoxide as the inhibitor of platelet activation. SS – side 
light scattering, parameter of platelets granulation: FS – frontal light scattering, parameter of platelets shape. Traces are typical for 3 
independent experiments made in triplicate.
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FIGURE 6. The acidification of platelets secretory granules and the release of granule constituents during adenosine diphosphate 
(ADP)-induced activation in the presence of platelet aggregation inhibitor from the Echis multisquamatis (PAIEM) snake venom. 
Platelets were loaded with pH-sensitive fluorescent dye acridine orange and stimulated with 2 μM of ADP in the presence or absence 
of PAIEM. Traces are typical for 5 independent experiments. A – after the addition of equivalent amount of buffer; B – in the presence 
of 10 μg/mL of PAIEM; C – in the presence of 1% dimethyl sulfoxide; D – summarized enlarged fragment of graphics A-C. Traces are 
typical for 3 independent experiments performed 5 times each.
FIGURE 7. A. Scheme of experiment that confirmed the platelet aggregation inhibitor from the Echis multisquamatis (PAIEM) snake 
venom binding to glycoprotein (GP)IIb/IIIa. Washed human platelets were added to the wells of 96-well tissue culture plate and 
then activated by 30 µM of adenosine diphosphate. Antibody CD61 (specific to IIb subunit of Iib/IIIa platelet receptor) was added 
to the first row of wells, antibody CD61 was added to the second row alongside with PAIEM (0.05 mg/mL). B. Enzyme-linked im-
munosorbent assay of anti-GPIIb binding to activated platelets in the presence of PAIEM. Boxes and whiskers represent the mean 
values ± standard error (data of 3 typical experiments performed 5 times each), *P < 0.05 as compared to the control.
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sis and atherothrombosis. Disintegrins received an atten-
tion for their potential clinical application to some diseases 
including thrombosis or cancer. The main function of dis-
integrins is their inhibitory action on platelet aggregation. 
Snake venom disintegrins were shown to be potent an-
ti-proliferative agents that prevent cancer cells adhesion 
(21,22). Some of them were successfully tested as anti-tu-
mor drugs in animal models (23).
It is well known that fibrinogen binds to the exposed inte-
grin GPIIb/IIIa on the platelet surface and mediates platelet 
interaction and aggregation (24). Disintegrin proved to in-
teract with integrin GPIIb/IIIa and act as fibrinogen recep-
tor antagonist. Thus, disintegrins can inhibit platelet ag-
gregation stimulated by several agonists including ADP, 
thrombin, and collagen. For example, the disintegrin con-
tortrostatin significantly prevents reocclusion in the canine 
carotid arterial thrombosis model (25,26). There are sever-
al reports on disintegrins from the venom of Echis multi-
squamatis. Previously, a C-lectin type antagonist of colla-
gen GPIa/IIa receptor (EMS16) with molecular weight of 
approximately 33 kDa was purified and characterized (27-
29). Protein with the same molecular weight was reported 
as fibrinogenase with platelet-modulating activity resulted 
from cleavage of N-terminal portions of Bβ-chain of fibrin-
ogen (30).
Another low-molecular weight protein with anti-aggre-
gatory activity was purified from the Echis multisquamatis 
venom. Authors determined the molecular weight of the 
protein as 5.7 kDa (31). It was characterized as anti-GPIIb/
IIIa RGD-containing peptide with IC50 determined as 97 
nM (32).
To summarize results, the low-molecular weight protein 
from Echis multisquamatis venom was shown to be an in-
hibitor of platelet aggregation. Isolated inhibitor effective-
ly suppresses platelet aggregation in platelet-rich plasma. 
It did not affect platelet activation or degranulation but 
prevented platelet aggregation by inhibiting of fibrino-
gen binding to GPIIb/IIIa receptor. We also showed a pro-
nounced inhibition of HeLa cells proliferation by PAIEM. We 
can assume that PAIEM inhibited the viability of HeLa cells 
possibly by blocking their integrin interactions. We can 
also assume that PAIEM could be a potential platform for 
the development of anti-thrombotic drugs as well as anti-
proliferative agents in anti-cancer therapy. Further studies 
of PAIEM action on cancer cells will help us to evaluate the 
possible use of this polypeptide in anti-cancer therapy.
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